Howard Mackey

Statistical Service — CY

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index4.1kcitations52works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hedgehog Signaling Pathway Studies(26), Cancer Mechanisms and Therapy(14), Statistical Methods in Clinical Trials(9), Alzheimer's disease research and treatments(8), Advanced Breast Cancer Therapies(8)

Publications52 total

Type I Error Control of an Adaptive Endpoint Selection Procedure
Statistics in Biopharmaceutical Research·2025Open Access
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy and safety of crenezumab
Alzheimer s & Dementia·2023· 1 citedOpen Access
Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 4 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 3 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Table 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 5 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Data from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Table 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure Legend from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 4 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure Legend from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 5 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Data from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 1 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 2 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Supplementary Figure 2 from A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
2023Open Access
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease
JAMA Neurology·2022· 197 citedOpen Access
Power and sample size for random coefficient regression models in randomized experiments with monotone missing data
Biometrical Journal·2021· 17 cited
page 1 of 3Next →

Frequent Co-authors

Jennifer A. Low(22), Robert L. Yauch(20), Richard Graham(16), Johanna C. Bendell(16), Lowell L. Hart(16), Irfan Firdaus(16), Ira Gore(16), Jordan Berlin(15), Mary F. Mulcahy(15), Mark M. Zalupski(15), Gordon L. Bray(15), Robert C. Hermann(14), Kaycee M. Sink(6), Charles M. Rudin(5), Walter C. Darbonne(5), Jillian Smith(5), Rachelle S. Doody(5), Thomas Bengtsson(5), Josina C. Reddy(4), Daniel D. Von Hoff(4)